Literature DB >> 10218547

Mineralocorticoid hypertension.

P M Stewart1.   

Abstract

Hypertension with hypokalaemia and suppression of plasma renin activity is known as mineralocorticoid hypertension. Although mineralocorticoid hypertension accounts for a small number of patients labelled as having "essential" hypertension, it is a potentially reversible cause of high blood pressure. The most common cause of mineralocorticoid hypertension is probably primary aldosteronism; controlled posture studies to measure plasma renin activity and aldosterone concentrations, followed by adrenal imaging, will ensure the differential diagnosis between an aldosterone-producing adenoma and idiopathic adrenal hyperplasia in most cases. Three monogenic forms of mineralocorticoid hypertension have been described: glucocorticoid-suppressible hyperaldosteronism, Liddle's syndrome, and apparent mineralocorticoid excess, which have provided new insights into mineralocorticoid hormone action. Many patients with mineralocorticoid-based hypertension are now known to have normal serum potassium concentrations. Until the true prevalence of primary aldosteronism and monogenic forms of mineralocorticoid hypertension are defined, a high index of suspicion is needed in every hypertensive patient. Hypertensive patients with hypokalaemia, together with those with severe hypertension or a family history of hypertension or stroke, should be screened for mineralocorticoid excess.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10218547     DOI: 10.1016/S0140-6736(98)06102-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  27 in total

Review 1.  Matching the right drug to the right patient in essential hypertension.

Authors:  M J Brown
Journal:  Heart       Date:  2001-07       Impact factor: 5.994

Review 2.  Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations.

Authors:  Arduino A Mangoni
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 3.  Drug-induced endocrine and metabolic disorders.

Authors:  Ronald C W Ma; Alice P S Kong; Norman Chan; Peter C Y Tong; Juliana C N Chan
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

4.  Adrenocortical carcinoma producing 11-deoxycorticosterone: a rare cause of mineralocorticoid hypertension.

Authors:  K Müssig; M Wehrmann; M Horger; C Maser-Gluth; H U Häring; D Overkamp
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

5.  Early hypertension and prolonged mineralocorticoid therapy discontinuation in a child with salt-wasting 21-hydroxylase deficiency.

Authors:  M Wasniewska; M Valenzise; T Aversa; S Mirabelli; F De Luca; F L De Luca; F Lombardo
Journal:  J Endocrinol Invest       Date:  2011-02       Impact factor: 4.256

6.  Antiaging Gene Klotho Regulates Adrenal CYP11B2 Expression and Aldosterone Synthesis.

Authors:  Xiaoli Zhou; Kai Chen; Yongjun Wang; Mariano Schuman; Han Lei; Zhongjie Sun
Journal:  J Am Soc Nephrol       Date:  2015-10-15       Impact factor: 10.121

7.  Primary hyperaldosteronism: a case of unilateral adrenal hyperplasia with contralateral incidentaloma.

Authors:  Sujit Vakkalanka; Andrew Zhao; Mohammed Samannodi
Journal:  BMJ Case Rep       Date:  2016-07-14

8.  Ectopic ACTH syndrome revealed as severe hypokalemia and persistent hypertension during the perioperative period: a case report.

Authors:  Shun Kishimoto; Kiichi Hirota; Hajime Segawa; Kazuhiko Fukuda
Journal:  J Anesth       Date:  2010-11-04       Impact factor: 2.078

Review 9.  Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism.

Authors:  Laurence Amar; Pierre-François Plouin; Olivier Steichen
Journal:  Orphanet J Rare Dis       Date:  2010-05-19       Impact factor: 4.123

Review 10.  Renin: friend or foe?

Authors:  Morris J Brown
Journal:  Heart       Date:  2007-05-08       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.